The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Crunch time approaches for UroGen.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
But sasanlimab's use looks set to remain narrow.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
AACR approaches, along with ASCO abstract titles.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Meanwhile, Tango tries again in PRMT5.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.